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Abstract

REACTIVE GLIOSIS FOLLOWING HIPPOCAMPAL IMPLANTATION:
A biocompatibility evaluation of five materials.
Karl A. Lozanne (Sponsored by Dennis D. Spencer). Department of Neurosurgery, Yale
University School of Medicine, New Haven, CT.

The present study aimed to determine the biocompatibility of several materials proposed
for the development of a novel intracranial biosensor. The glial reaction induced by short¬
term (14 day) and long-term (90 day) implantation of potential biosensor substrates,
namely carbon, silicon, gold, platinum and Pyrex, into the hippocampus was measured
and characterized. Needle shaped implants of each material, 0.5 mm in diameter, were
implanted into the hippocampi of adult rats for 14 or 90 days. Glial fibrillary acidic
protein immunohistochemistry coupled with mean optical density (MOD) measurements
were used to determine the level of reactive gliosis following implantation. The extent of
gliosis varied depending on the implant type and was lowest for platinum followed in
increasing level by gold, carbon, silicon, and Pyrex. The glial reaction decreased in
volume over time for each substrate except Pyrex, leaving behind a thin, porous glial
membrane at the brain-implant boundary. We conclude that platinum and gold are the
best substrates for a chronically implanted neural biosensor, but that carbon and silicon
are also suitable. We caution against the long-term use of Pyrex as a substrate because a
chronic glial reaction develops following its implantation.

K. Lozanne
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Introduction
Extracellular concentrations of neurotransmitters reflect the balance between the rate of
neurotransmitter release from presynaptic vesicles and the rate of uptake into adjacent
neurons and glia.

Microdialysis, a technique which measures the extracellular

concentrations of neurotransmitters or other compounds in the brains of awake,
ambulatory animals, following the stereotactical introduction of microdialysis probes into
specific brain regions, has allowed greater insight into the biochemical milieu of the brain
(Benveniste 1989; Benveniste, Hansen et al. 1989; Benveniste and Huttemeier 1990;
Maggs, Borg et al. 1997; Chapman 1998),

When coupled with models of ischemia,

trauma, and seizure disorders, microdialysis has provided insight into the local
biochemical derangement that accompanies these CNS disorders (Benveniste, Hansen et
al. 1989; Chapman 1998).

In 1991, the first human in vivo biochemical measurements of the effects of spontaneous
seizures in the human brain extracellular environment were performed at Yale by
attaching a microdialysis membrane to the depth electrodes of patients undergoing
evaluation for surgically remediable, medically intractable epilepsy (During 1991).
Besides helping to establish microdialysis use in the study of human CNS disease, this
and subsequent studies helped identify adenosine, glutamate, GABA, lactate and pH as
mediators involved in seizure onset, spread, and spontaneous arrest (During and Spencer
1992; During and Spencer 1993; During, Fried et al. 1994).
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Despite the insight provided by these studies, the measurements obtained have been
limited in scope mainly due to the limitations of off-line microdialysis techniques.
Microdialysis relies on a rapid exchange of small molecules across a semipermeable
membrane (typically 10-30 mm long in humans) that is implanted into an extracellular
space several orders of magnitude larger than the dimension of the synaptic cleft.
Furthermore, the time resolution (2-5 mins) is orders of magnitude slower than synaptic
events (Chapman 1998).

Considering these limitations, investigators have been led to

seek more accurate and detailed information to answer the following questions.

Do

concentrations of identified mediators involved in seizure activity fluctuate in the
immediate moments prior to seizure onset?

Are there threshold levels in the

concentration of these mediators at which an ictal event is imperative? What influence
do the concentrations and fluctuations of glucose and CF have on seizure onset, spread,
and spontaneous arrest? What role does pH play? Answers to these questions require
continuous measurement of the dynamic changes in the extracellular biochemical
environment of a seizure focus. Despite the usefulness and continued refinement of brain
microdialysis technique (Benveniste 1989), new technology is necessary to accurately
characterize the peri-ictal molecular environment.

Statement of Purpose
In collaboration with the Dept, of Engineering at Yale, a project to develop an
electromolecular

sensing

probe

that

can

measure

the

dynamic

changes

in
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neurotransmitters, lactate, pH, O2, glucose and other molecules simultaneously with
electrical variations was begun.

The present study is a preliminary evaluation of

biocompatibility for some of the materials proposed as the substrate for this biosensing
device.

In particular, this study measured the extent of reactive gliosis in the

hippocampus incurred by implantation of carbon, silicon, gold, platinum and Pyrex,
materials that are well established in microelectronics.

Reactive gliosis
In response to CNS trauma of any kind, including the introduction of foreign material,
there is a rapid, local, multicellular response dominated by astrocyte proliferation
(Kumar, Robbins et al. 1999). During this reactive astrocytosis (a.k.a. reactive gliosis),
astrocytes proliferate and increase in size, their cytoplasmic processes become larger and
more tortuous, and there is a substantial increase in the number of intermediate glial
filaments and in glial fibrillary acidic protein (GFAP) content (Eng 1985; Arnold, Franz
et al 1996). Immunohistochemical methods for the detection of GFAP, the major protein
constituent of glial intermediate filaments in differentiated astrocytes, have been
extensively used for the study of reactive gliosis (Eng, Smith et al. 1985).

Previous studies relying on conventional techniques, including cell counting and
proximity of neurons, have revealed an inconsistent pattern of reactive gliosis following
the implantation of foreign material into the brain. This variation has been attributed to
the trauma of implantation and the toxicity of the materials implanted (Stensaas and
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Stensaas 1976; Stensaas and Stensaas 1978; Del Bigio and Bruni 1986; Benveniste and
Diemer 1987; Edell, Toi et al. 1992; Schmidt, Horch et al. 1993; Menei, Croue et al.
1994; Yuen and Agnew 1995; Emerich, Tracy et al. 1999).

In the present study, an

attempt at an objective quantification of the reactive gliosis following hippocampal
implantation of carbon, silicon, gold, platinum and Pyrex is undertaken by combining
GFAP iinmunohistochemistry with optical density measurements.

Materials and Methods
Implant Materials
Uncoated pure platinum wire and gold wire, .5 mm in diameter, were purchased from
World Precision Instruments, Inc. (Florida, USA).
diameter mechanical pencil lead from Staples.

Carbon was purchased as .5 mm

Silicon and Pyrex pieces, .5 mm in

diameter, were obtained from the Electrical Engineering Department at Yale College.
One end of each implant was cut, broken, or ground into a needle-shaped edge.

Implantation
Prior to implantation, each implant was bathed in ethanol and allowed to air dry for 5-10
minutes.

Adult male Sprague-Dawley rats (Charles River Laboratories, MA, USA),

weighing 250-300 g were anesthetized with an injection of Ketamine (60 mg/kg, IM)
followed by Pentobarbital (20 mg/kg, IP) and mounted on a small animal stereotaxic
instrument (David Kopf Instruments, CA, USA).

Under aseptic conditions, a midline
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incision was made in the scalp and the bregma was identified. With the aid of a burr-drill,
two small craniotomies were made 3.6 mm posterior to the bregma, bilaterally at 2.7 mm
from the midline. One needle shaped implants was implanted into each hippocampus by
slowly (1 mm/ 30 s) advancing the implant 3.8 mm deep into the burr hole.

The

externalized portion of the implants were stabilized against the skull by application of
instant adhesive glue and accelerator. For additional stabilization, once the glue was dry,
a small screw was inserted into the skull 2 mm posterior to the lambda and the wound
was covered with denture resin. To simulate trauma alone, a gold implant was implanted
in the animal’s hippocampus using the technique described above, tapped 10 times and
extracted prior to glue and denture resin application.
Each animal received 100,000 lU/kg S.Q. Flocillin antibiotic immediately following the
procedure and was subsequently housed in a single animal cage maintained in a
temperature- and humidity-controlled colony room. Post-surgical analgesia consisted of 4
days of Tylenol 0.32 mg/ml via water bottle. Food and water were available ad lib during
the experiment

The Yale University Institutional Animal Care and Use Committee

approved all procedures.

Histology
Animals were sacrificed at 14 and 90 days following implantation

Following a lethal

intraperitoneal injection of pentobarbital of at least 150 mg/kg, rats were transcardially
perfused with an aldehyde solution containing 4% paraformaldehyde with the aid of a
Masterflex pump (Cole-Parmer Instrument Company, IL, USA).

The implants were

6
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extracted and intact brains were then removed and immersed in the same fixative for 1 to
3 days. One day prior to sectioning, the brain was immersed in a 30% sucrose solution.
Using a microtome, frozen 60 |im thick coronal sections of the brain areas that previously
contained the implants were cut and mounted on glass slides.

Immunohistochemistry
After thorough washing in 0.1M Tris-HCl buffer containing 0.3% Triton X-100 (Sigma),
sections were exposed to a block solution containing 2% bovine serum albumin (Sigma)
in the washing solution for approximately 1 hour. Sections were then exposed to a rabbit
primary monoclonal antibody directed against glial fibrillary acidic protein (GFAP 1:500,
Sigma) overnight at 4° C. Following washing, sections were incubated with anti-rabbit
secondary biotinylated antibody (Sigma) at room temperature for 1 h and then an
avidimbiotin enzyme complex (Vector Labs, CA, USA) for 1 h. The catalyzed signal
amplification was employed to enhance the immunostaining. After rinsing, the reaction
was developed using 3,3’-diaminobenzidine tetrahydrochloride (Sigma) and hydrogen
peroxide at room temperature. Sections were then dehydrated and mounted in DPX
(Sigma).

Optical Density Measurements
Pictures of each immunostained slide were taken and converted to gray scale digital
images using an Olympus Magnafire digital microimaging system (Olympus America
Inc., NY, USA).

Using Scion Image software (Scion Corp.), mean optical density

K. Lozanne
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(MOD) measurements were taken of 2000 (am regions in 1) the corpus callosum and; 2)
three zones adjacent to the implant track- zone 1 from implant boundary out 100 pm,
zone 2 100 pm to 200 pm from boundary, zone 3 200 pm to 300 pm from boundary
(Figure 1). For each animal, ratios of MOD in the corpus callosum to MOD in each of
the three zones were calculated.

The average of the mean optical density ratios (avg.

MODR) for each study group was then calculated and used in between group
comparisons. For control and trauma samples, since no implant track was available to
determine the three zones, the MOD of four 2000 pm2 regions corresponding to the
hippocampal implant sites were taken and averaged.

This average was then used to

calculate a ratio of mean optical density in the corpus callosum to mean optical density in
the hippocampus. Using the method of calculating mean optical density ratios mentioned
above, higher MOD ratios correspond to higher levels of reactive gliosis. MOD ratios,
rather than the absolute MOD values, were used for comparisons to adjust for varying
intensities of staining between samples.

K. Lozanne
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Figure 1. Calculation of mean optical density (MOD) at zone 1, zone 2, and zone 3.
MODs were measured for a 100mm x 200mm area of the corpus callosum and for each of three zones
adjacent to the implant track. Ratios for each zone were calculated using the following equation
MOD Ratio= MOD Corpus
MOD Zone

No statistical analysis of mean optical density measurements was undertaken because of
the low number of animals that were included in the study. Therefore, conclusions are
drawn mostly from histological analysis with average MOD ratio measurements used to
confirm gross histological findings.

The

author

conducted

all

animal

surgeries,

preparation

of

reagents,

immunohistochemistry, and optical density measurements. The author performed most
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transcardial perfusions and microtome sectioning of tissue on his own with help from
Dolores Montoya of the Dept, of Neurosurgery when available.

Results
No overt neurological changes were seen in the rats following implantation. There were
no deaths or signs of infection throughout the study period Nine animals lost their dental
cement caps prior to completing their study interval. Included in the final analysis were
1) animals who maintained an intact dental cement cap throughout the study period; 2)
tissue slice preparations that showed immunocytochemical staining adequate for
morphological and optical density evaluation (i.e, GFAP specific immunoreactivity with
good astrocyte morphology throughout hippocampus and corpus callosum). Evaluation
of intermediate study intervals (30 and 60 day) were limited by technical difficulties.

Controls
Small, GFAP immunoreactive cells were found diffusely throughout the brain slices but
were most prominent within the cortex and along the corpus callosum. Within the
hippocampus, the polymorphic layer of the dentate gyrus consistently stained darker than
adjacent regions, however, no distinct clustering of GFAP immunoreactive cells were
seen within the hippocampus (Figure 2).

This pattern of GFAP immunoreactivity in

normal adult rat brains is consistent with previous studies (Benveniste and Diemer 1987;
Gammer, Tansey et al. 1990).

K. Lozanne
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Figure 2. Immunohistochemical staining for glial fibrillary acidic protein (GFAP) in hippocampus of
control specimen. Note the darker staining polymorphic layer of the dentate gyrus (PoDG) with
small GFAP imniunoreactive astrocytes (arrows) hut no distinct clustering of cells (GFAP 1:500
100X).

14 day implants
Similar to control slices, the polymorphic layer of the dentate gyrus in implant specimens
stained darker than adjacent regions.

For all implant types, however,

GFAP

imniunoreactive cells clustered around the site of implantation. In particular, GFAP
immunoreactivity was most prominent along the implant-brain boundary (Figure 3).
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Figure 3. GFAP immunoreactive astrocytes at implant-brain boundary 14 days post-implantation.
Images show reactive gliosis with clustering of large astrocytes around site of implantation (arrows).
Note the less intense reactive gliosis for the platinum and gold implants (A, B). Also note the
clustering of large astrocytes and pockets of hemorrhage where trauma was simulated (F, curved
arrow) (GFAP 1:500 100X).
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In general, implant-brain boundaries revealed large astrocytes immediately adjacent to
the implant tracks.

Hypertrophic processes originating from these astrocytes could be

seen extending towards the site of implantation. At increasing distances from the implant
track, the size of the astrocytes and their processes decreased with a return to the typical
sizes seen in control specimens at distances greater than 275-300 pm (Figure 4).

Figure 4. Reactive gliosis close to the site of gold implantation (implantation site to the left of image).
Large astrocytes with hypertrophic processes (white arrow) can be seen closer to the site of
implantation with decreased levels of reactive gliosis and decreases in the size of astrocyte processes
at increasing distance from the implant site (black arrow).

13
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Levels of GFAP immunoreactivity varied according to the implant type (platinum, gold,
carbon, silicon, or Pyrex implant). Of the materials studied, platinum appears to have the
least dense level of GFAP immunoreactivity at the boundary and adjacent regions.
Despite the characteristic increased density and clustering of GFAP immunoreactive cells
seen in implanted specimens, no distinct, confluent layer of astrocytes is seen at the
platinum-brain boundary. Unlike platinum, the Pyrex-brain boundary is characterized by
densely packed large astrocytes forming a wall approximately 10 to 25 pm thick around
the implant. Close examination of the Pyrex-brain boundary revealed that the apparent
capsule is porous, with some gaps measuring greater than 50 pm in diameter (Figure 5).
The remaining implant types showed levels of GFAP immunoreactivity between those
seen for platinum and Pyrex, with the level for gold appearing the most similar to that for
platinum and the level for carbon being the most similar, but not as heavy, as that for
Pyrex.

14
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Figure 5. Increasing magnification of
glial barrier at Pyrex-brain implant
boundary. Note the porosity of the
barrier.
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In areas of the hippocampus where trauma was simulated, a diffusely increased level of
GFAP immunoreactivity was apparent. Clustering of large GFAP immunoreactive cells
could be seen, often accompanied by pockets of hemorrhage (Figure 3. F).

Measurements of mean optical

density ratios

(MODRs) corroborated the

gross

observations for the 14-day implants and confirmed that platinum was the implant type
incurring the least amount of reactive gliosis (average MODR in zone 1= 1.01; Table 1).
Platinum was followed in increasing level of average MODR by gold, carbon, silicon,
and Pyrex (average MODRs in zone 1 of 1.06, 1,11, 1.12, and 1.16, respectively)

All

implant types, including simulated trauma, displayed average MODRs greater than
controls. Platinum-implanted specimens had an average MODR comparable to that of
simulated trauma specimens (1.01 and 1.05 for platinum and trauma respectively).

MODRs decreased successively at 100-200 pm (Zone 2) and 200-300 pm (Zone 3)
radius from the brain-implant boundaries for each implant type. Despite this decrease, the
average MODRs at 200-300 pm radius for each implant type is still higher than that of
control.

16
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Table 1. Average mean optical density ratios for each of the zones adjacent to the implant-brain
boundary at 14 and 90 days post-implantation.

90 day implants
In general, the levels of GFAP immunoreactivity seen in the hippocampus at 90 days
post-implantation appear lower than that seen at 14 days post-implantation. The reaction
immediately surrounding the implants remained dense but began to decrease in total area.
Clusters of large astrocytes with hypertrophied processes can still be seen immediately
adjacent to implant tracks but small astrocytes, consistent in size with those seen in
control specimens, dominated regions as close as 200 pm from the implant-brain
boundary (Figure 6).

17
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Figure 6. GFAP immunoreactive astrocytes at implant-brain boundary 90 days post-implantation.
Large astrocytes are more localized to areas immediately adjacent to implant site compared to 14
day counterparts (white arrows). A densely packed thin layer of astrocytes at each implant-brain
boundary appears to form a barrier between brain and implant (black arrows). Note the small area
of clustered astrocytes still apparent at the site of simulated trauma (F, curved arrow) (GFAP 1:500
100X).

K. Lozanne

18

Platinum and gold, once again, appeared to incur the lowest levels of reactive gliosis with
Pyrex on the opposite side of the spectrum.

The increased duration of implantation,

however, appeared to allow time for a more consolidated, yet thinner, boundary of
reactive astrocytes for each implant type.

Despite this, the apparent “barriers” which

developed continued to display the porosity seen with the 14-day implants.

Where trauma was simulated, increased levels of GFAP immunoreactivity and large,
hypertrophied astrocytes were still observed at 90 days. However, in contrast to their 14day counterparts, the clusters of large GFAP immunoreactive cells seen in 90-day postsimulated trauma specimens appeared to be more concentrated, spanning smaller areas.
Furthermore, at 90 days, signs of hemorrhage were no longer apparent in any of the
studied trauma specimens.

Average MODRs for our long-term implants confirmed most of our gross observations.
The 90-day average MODRs within 100pm (Zone 1) of the implant track for each of the
implant materials, except Pyrex, decreased relative to the 14-day measurements (Table 1;
Figure 7).

This decrease was also seen in the simulated trauma specimens. Similar

decreases in average MODR were seen at 100-200pm (Zone 2) and 200-300pm (Zone 3)
for all implant materials, except Pyrex, whose MODR levels in the more distant zones
remained similar to levels seen at 14 days.
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Platinum proved once again to be the least reactive material with an average MODR
within 100 pm (Zone 1) of 0.66.

Pyrex showed the highest amount of reactive gliosis

with an average MODR of 1.32. This time, however, platinum was followed in increasing
reactivity by gold, silicon, and then carbon (average MODRs of 0.92, 1.03, 1.04, for gold,
silicon, and carbon respectively). For platinum in particular, the average MODRs in the
immediately adjacent zone was comparable to that seen for control specimens (0.66 for
platinum versus 0.86 seen in controls) and substantially lower than that seen for
simulated trauma (0.66 versus 0.91).

Pyrex was the only implant type for which an

increase in the average MODR for the long-term implant, when compared to the short¬
term implant, was seen (1.32 up from 116).

Figure 7. Average mean optical density ratios (MODRs) at 90 days post-implantation relative to 14
days for each zone adjacent to implant-brain boundary. The average MODRs are plotted on the yaxis with zones 1, 2, 3 for each implant type adjacent to each other. The negative deflection at 14
days for zone 1 of the Pyrex implant reflects an increase in average MODR at 90 days relative to 14day levels.

K. Lozanne
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Discussion
A critical factor in the development and long-term effectiveness of implantable
intracranial devices is the development of appropriate biomaterials that directly contact
the nervous tissue.

Previous studies have revealed that while many materials are non¬

reactive and produce little to no parenchymal alterations, others induce varying degrees
of reactive changes through local toxic effects (Stensaas and Stensaas 1976; Stensaas and
Stensaas 1978). The present study is consistent with these findings.

We acknowledge the difficulty in making conclusions regarding the long-term platinum
and gold implants considering the low number of specimens that underwent complete
evaluation with these implant types. Difficulties with maintaining intact implants in vivo
throughout the study periods and technical difficulties with immunohistochemistry
resulted in small study groups.

However, we feel justified in drawing the following

conclusions in that the differences in the histological and mean optical density evaluation
between these and the other implant types was not only striking, but also consistent with
the differences seen in the short-term implants.

We demonstrate that implantation of carbon, silicon, gold, platinum or Pyrex into
hippocampus induces a local glial reaction present at 14 days that is generally
characterized by the accumulation of large astrocytes clustering into a porous glial barrier
at the implant-brain boundary.

Platinum showed the least amount of reactive gliosis

followed by gold, carbon, silicon, and Pyrex.

The area of gliosis decreased in volume

21
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and localized to the implant-brain boundary for each implant type except Pyrex.
Complete resolution of reaction can be seen within 100 pm for the platinum and gold
implants, and within 300 pm of the silicon and carbon implants at 90 days. The reactive
gliosis induced by platinum and that induced by gold, appear to be due in large part to the
trauma of implantation rather than intrinsic toxicity.

For silicon, carbon, and Pyrex,

intrinsic characteristics of the material implanted, in addition to the trauma of
implantation, appear to contribute to the level of reactive gliosis.
Using persistence of reactive gliosis at >15 pm from the implant-brain barrier at 90 days
post-implantation as a measure of toxicity, platinum and gold appear to be non-toxic,
while silicon and carbon show slight toxicity. Pyrex appears to be toxic to brain tissue
since, unlike the other materials, no resolution to the reactive gliosis incurred by Pyrex
implantation was seen at 90 days.

Implantation of foreign material induces local gliosis present at 14 days.
All studies looking at biocompatibility of implanted materials have shown that an acute
local glial reaction occurs at the site of implantation. Collias and Manuelidas (1957), two
weeks after implanting non-toxic multilead electrodes into cats, noted swollen astrocytes
surrounding the implants. Similar results were reported following implantation of plastic
needles (araldite) (Stensaas and Stensaas 1976), microdialysis tubes (Benveniste and
Diemer 1987), and polymer microspheres (Emerich, Tracy et al. 1999) into the brain.
The present study is consistent with these findings. At 14 days, each of the implanted

22

materials exhibited a local

glial reaction characterized

K. Lozanne

by large astrocytes and

hypertrophic astrocyte processes.

It is conceivable that the acute glial reaction is largely due to the trauma of implantation.
During implantation, tissue must be torn, cut, stretched, or compressed by the material
being introduced.

Non-smooth implant surfaces may contribute to these processes.

Tearing, in particular, could cause damage to cell membranes causing death and release
of intracellular mediators of inflammation and gliosis. In addition, damage to capillaries
as the implant traverses the brain parenchyma can lead to microhemorrhages with
resultant release of additional inflammatory factors and potential damage to parenchymal
cells. Edell, Toi, et al. (Edell, Toi et al. 1992) propose that any feature of an implant that
is larger than a few tens of angstroms may catch on filamentous structures which could
cause propagation of forces into adjacent structures and result in tissue damage.
Considering this extreme size demand, even nonreactive implants, should be expected to
induce, at least, a minimal reaction acutely. Each material implanted in the present study
induced a glial reaction that was visible at 14 days. Thus, a baseline level of reactive
gliosis can be attributable to the trauma of implantation, with variations in reaction above
this level attributable to intrinsic toxic characteristics of the implanted material.

Reaction leads to the production of a glial membrane surrounding the implant.
The implant boundary for each of the implants in this study is characterized by densely
packed large astrocytes forming a glial barrier. This GFAP- rich zone has been noted in

K. Lozanne
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previous studies (Schmidt, Horch et al. 1993; Menei, Croue et al. 1994; Liu, McCreery et
al. 1999; Kristensen, Noraberg et al. 2001) and is frequently referred to as a capsule.
Edell, Toi et al. found 5 to 75 pm thick, and sometimes up to 250 pm thick glial
“capsules” around insulator-coated metal conical shafts that were inserted into cortex
(Edell, Toi et al. 1992).

On the other hand, Liu, McCreery et al. found negligible

encapsulation around exposed electrode tips implanted into cortex (Liu, McCreery et al.
1999). Consistent with the variation seen in previous studies, our study shows that the
GFAP-rich zone at the implant boundary varies in thickness depending on implant type.
This variation reflects the different intrinsic toxicity of the various materials.

Our study further suggests, that this boundary is not stable. The GFAP-rich zone
surrounding platinum implants was never greater than 7 pm thick for both short-term and
long-term implants.

However, the GFAP-rich zone surrounding Pyrex, showed a

maximum thickness of 37 pm (range 30 to 37 pm) at 14 days and a maximum thickness
of 30 pm (range 25 to 30pm) at 90 days. Result from the study by Liu, McCreery et al.
indicates that the implant-tissue interface may change from day-to-day over the first 1-2
weeks, week-to-week for 1-2 months, and become quite stable thereafter. A variety of
mechanisms may contribute to this initial instability.

Microtrauma, from movement of

the brain relative to the implant, or vice versa, is an explanation that must be considered.

24
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The glial membrane is porous.
Close examination of the GFAP-rich zone surrounding Pyrex implants in our study
revealed that the glial barrier is porous, with some gaps measuring greater than 50pm in
diameter. For this reason, we’ve refrained from calling the glial barrier a “capsule”, since
it is not confluent and bears more of a resemblance to a semipermeable membrane than a
capsule.

The porosity of this glial membrane is relevant to the development of any

biosensing device because direct communication between the sensing elements and the
extracellular fluid is essential.

Reactive gliosis decreased over time for all implants except Pyrex.
Though gliosis is still seen at 90 days post-implantation for all materials studied, the
volume of the reaction decreased substantially for platinum and gold implants, decreased
moderately for silicon and carbon implants, but remained constant for Pyrex implants.
For the least reactive materials, the glial reaction resolved except for a thin layer of
astrocytes at the implant-brain boundary.

Consistent with our study, Stensaas and

Steensaas, in their histopathologic evaluation of several materials implanted into the
cerebral cortex for up to 723 days, found a narrow zone of astrocyte processes at the
implant surface of non-reactive materials (Stensaas and Stensaas 1978). The finding at 90
days of astrocyte clustering where trauma was previously simulated suggests that the
thin, porous glial membrane seen surrounding the least reactive implants (platinum and
gold) is likely a remnant of the reaction to the trauma of implantation- a glial scar, and
not representative of an active glial reaction to the implant.
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Pyrex, on the other hand, displayed no relative change in the volume of reaction 90 days
after implantation. The level of reaction is substantially greater than that seen 90 days
following simulated trauma. This suggests that an active reactive gliosis, not only glial
remnants of implantation trauma, persists after long-term implantation of Pyrex. Intrinsic
toxicity of Pyrex is the likely cause of this persistent reaction.

On building a biosensor.
From the present preliminary biocompatibility evaluation, we conclude that platinum and
gold are the best substrates for a chronically implanted intracranial biosensor.

Silicon

and carbon appear to be suitable materials for direct contact with brain tissue but the use
of Pyrex is cautioned against since its direct contact with brain tissue induces a chronic
reactive gliosis.

If Pyrex is to be used in the final construct, its apposition with brain

tissue should be avoided.

We realize that the biocompatibility of any implantable device is not limited to non¬
toxicity, and that investigations into the whole behavior of the implant in its biological
environment will need to be undertaken. Additional considerations include the long-term
effect of the brain on the implant and, conversely, the long-term effects of the implant on
the brain and other systems.

In particular, the corrosive effects of the in vivo

environment and enzymatic breakdown of device components need to be analyzed.
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Furthermore, the effect of chronic device implantation and use on the blood brain barrier,
metabolism, biochemistry, as well as morphology of the CNS must be studied.

It is feasible, considering present sensor and microelectronic technologies, and the
availability of biocompatible materials, to have an implantable construct that would allow
accurate, real-time measurements of neurotransmitters, lactate, glucose, pH, O2, and other
molecules.

We imagine that in the future, such a device would not only be used as a

diagnostic tool but, when coupled with a microinfusion mechanism, may provide a
therapeutic alternative in the treatment of several CNS diseases by allowing the
recreation of homeostasis at the site of CNS pathology
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